In vitro experiments revealed that Zanamivir substance had high antiviral activity against infection induced by genotypes 2.2 and 2.3.2 of highly virulent influenza A/H5N1 virus in the porcine embryonic renal epithelial (PERE) cell cultures. Zanamivir at used concentrations (1.0 microg/ml or lower) had no cytotoxic properties and was equally highly effective when used for prevention (1 hour prior to cell inoculation), treatment-and-prevention (at the time of cell inoculation), and treatment (2 hours after inoculation). The high antiviral potential of Zanamivir was shown in the experiments dealing with its effect on the ability of infected PERE cells to produce an infectious virus in the first 24 hours after inoculation. The findings suggest that Zanamivir (Relenza) shows promise as an effective antiinfluenza agent.